방법 비교
선택한 방법을 나란히 검토하세요. 서로 다른 행은 강조 표시됩니다.
| 비용-편익 분석(CBA)× | 의료 경제학에서의 마르코프 연쇄 모형× | |
|---|---|---|
| 분야 | 보건경제학 | 보건경제학 |
| 계열 | Process / pipeline | Process / pipeline |
| 기원 연도≠ | 1970s | 1983 |
| 창시자≠ | Boardman, Greenberg, and colleagues (welfare economics) | Beck & Pauker (medical decision analysis, Massachusetts General Hospital) |
| 유형 | Method | Method |
| 원전≠ | Boardman, A. E., Greenberg, D. H., Vining, A. R., & Weimer, D. L. (2018). Cost-Benefit Analysis: Concepts and Practice (5th ed.). Cambridge: Cambridge University Press. link ↗ | Beck, J. R., & Pauker, S. G. (1983). The Markov Process in Medical Prognosis. Medical Decision Making, 3(4), 419-458. DOI ↗ |
| 별칭 | CBA, economic appraisal, benefit-cost ratio | Markov model, state transition model, cohort simulation |
| 관련 | 5 | 5 |
| 요약≠ | Cost-benefit analysis compares the total monetary value of benefits produced by a program against its total monetary costs, reporting net present value (NPV) or benefit-cost ratio (BCR). Rooted in welfare economics and used extensively in public policy (transportation, environmental, education, health), CBA answers the question: 'Is this program worth doing from a societal perspective?' Unlike cost-effectiveness analysis, CBA monetizes both costs and benefits, enabling comparison across disparate program types. | A Markov model is a decision-analytic tool that simulates disease progression through defined health states over time, calculating cumulative costs and quality-adjusted life years (QALYs) to enable cost-effectiveness analysis. Developed by Beck and Pauker in 1983, Markov models are now the standard framework for projecting long-term outcomes of health interventions, especially chronic diseases where patients transition between clinical states (treatment response, disease progression, remission, death). Used by health technology assessment bodies and pharmaceutical companies to predict intervention value beyond trial duration. |
| ScholarGate데이터셋 ↗ |
|
|